Can-Fite granted abstract award for Namodenoson to treat HCC by ASCO

Can-Fite BioPharma announced its abstract titled “A novel approach for the treatment of advanced hepatocellular carcinoma or HCC is one of the highest scoring abstracts and has won the prestigious Breakthrough Abstract Award from Conquer Cancer, the ASCO Foundation, and the 2023 ASCO Breakthrough Program Committee. Can-Fite’s Chief Scientific Officer, Founder, and Executive Chairman, Dr. Pnina Fishman, will present the poster at the ASCO Breakthrough Meeting which will take place August 3 – 5, 2023 in Yokohama, Japan. Namodenoson has received significant acknowledgment in the scientific and medical community, as evidenced by the numerous peer-reviewed publications and conferences in which it has been published and presented. Currently being evaluated in a pivotal Phase 3 multinational registration trial for the treatment of HCC and underlying Child Pugh B7, Namodenoson has also completely cleared cancer in an HCC patient who was enrolled in Can-Fite’s Phase 2b HCC trial. The patient continues to be treated through a compassionate use program in Romania, where she remains cancer-free more than six years following her first dose of Namodenoson. “We are honored to receive this prestigious award from Conquer Cancer and ASCO,” Dr. Fishman stated. “Our Phase 3 registration trial is designed to treat patients who have tried, yet not benefitted from the few other FDA-approved HCC treatments on the market today. We are hopeful that Namodenoson, with its liver-protective properties, can safely prolong life for advanced liver cancer patients.”